StemRIM
Fiscal Year Ending July 2026 Financial Summary
Announces the FY2026 July results overview and business development activities. Cash and deposits of 5.3 billion yen, annual expenditure around 1.6 billion yen, and R&D expenditure about 1.49 billion yen. No revenue recognition from operations, no milestone income or upfront payments. Reports progress on the new pipeline and IP strategy, and progress on SR-GT1. Outlines future funding measures and development plans through 2028.
Key Figures
- Cash and deposits balance: 5.3 billion yen (as of end of July 2026)
- Annual R&D expenses: 1.49 billion yen (year-long period Aug 2025–Jul 2026)
- Outlook for expenditures: 1.6 billion yen (full-year FY2026, R&D 1.4 billion yen, SG&A 0.26 billion yen)
AI要約
Overview of the financial results
The FY2026 July results summary notes that no business revenue is generated and no milestone income or upfront payments are recognized. Cash and deposits amount to 5.3 billion yen, establishing a financially solid base to support stable R&D activities through 2028. Annual expenditures are around 1.6 billion yen, mainly comprising R&D costs.
Business development / IP / Outlook
Progress in clinical development centered on Ledasemchod and SR-GT1, with IP strategy advancement reported. Disclosure of results from additional Phase 2/Phase 2b, milestones such as orphan drug designation, and ongoing clinical trial progress. Going forward, development plans aiming for product launch in 2028, and anticipated creation of collaboration research and license revenue.
StemRIM Inc.
Company overview · Stock price · Financial data · All IR
